CYC065 Cyclin Dependent Kinase Inhibitor Fadraciclib Cas 1070790-89-4
CYC065 Cyclin Dependent Kinase Inhibitor Fadraciclib Cas 1070790-89-4
+ AII PRODUCTS
- Prostaglandins - Custom Synthesis - PARP Inhibitors - PI3K Inhibitors - FAK Inhibitors - AKT Inhibitors - C-Kit Inhibitors - VEGFR Inhibitors - c-Met Inhibitors - CDK Inhibitors - CYP17 Inhibitors - DNA/RNA Inhibitors - mTOR Inhibitors - SRC Inhibitors - Others
Product
|
Size |
Price |
Stock |
Quantity |
|---|---|---|---|
|
Get Quotation Now Add to Cart Bulk Inquiry |
|||
AddThis Sharing Buttons
Share to FacebookFacebookShare to TwitterTwitterShare to PrintPrintShare to EmailEmailShare to PinterestPinterestShare to GmailGmailShare to LinkedInLinkedInShare to Email AppEmail AppShare to TumblrTumblrShare to MoreAddThis
Shipping and handling fee USD40, Free delivery is qualified when the total value of your order exceeds USD500.If the item is temporarily out of stock. Please email to order@pharm-intermediates.com,we will inform you when we have it in stock.
Chemical Information
|
Product name:CYC065 Fadraciclib |
Purity:98.0% min |
|
CAS NO:1070790-89-4 |
Solubility:DMSO100 mg/mL (251.56 mM) |
|
Molecular Formula:C21H31N7O |
Package:Package according to customer requirements |
|
Molecular Weight:397.517 |
Storage:Store at -20℃ |
Quality control
Remarks
Fadraciclib, also known as CYC065, is an orally bioavailable inhibitor of cyclin dependent kinases 2, 5 and 9 (CDK2/5/9) with potential antineoplastic and chemoprotective activities. CYC065 selectively binds to and inhibits the activity of CDK2, 5 and 9, which leads to inhibition of CDK2, 5 and 9-dependent cellular pathways, downregulation of genes involved in the pro-survival pathway, prevention of the activation of DNA double-strand break repair pathways, and induction of both cell cycle arrest and apoptosis.
This inhibits the proliferation of CDK2/5/9-overexpressing tumor cells. In addition, CYC065 protects hematopoietic stem and progenitor cells (HSPCs), prevents myelosuppression, and preserves the function of the bone marrow.
Chemical Properties:
Boiling point: 618.3±65.0 °C(Predicted)
density: 1.25±0.1 g/cm3(Predicted)
pka: 14.62±0.20(Predicted)
References
[1].Cocco E, et al. Dual CCNE1/PIK3CA targeting is synergistic in CCNE1-amplified/PIK3CA-mutated uterine serous carcinomas in vitro and in vivo. Br J Cancer. 2016 Jul 26;115(3):303-11.
[2].Sumana Devata, et al. Molecular markers and venous thromboembolism (VTE) in acute myelogenous leukemia (AML)
Get in Touch
Have questions about our products or want to discuss a custom order? Our team is ready to help you.